Association of long QT syndrome loci and cardiac events among patients treated with β-blockers

Silvia G. Priori, Carlo Napolitano, Peter J. Schwartz, Massimiliano Grillo, Raffaella Bloise, Elena Ronchetti, Cinzia Moncalvo, Chiara Tulipani, Alessia Veia, Georgia Bottelli, Janni Nastoli

Research output: Contribution to journalArticlepeer-review


Context: Data on the efficacy of β-blockers in the 3 most common genetic long QT syndrome (LQTS) loci are limited. Objective: To describe and assess outcome in a large systematically genotyped population of β-blocker-treated LQTS patients. Design, Setting, and Patients: Consecutive LQTS-genotyped patients (n=335) in Italy treated with β-blockers for an average of 5 years. Main Outcome Measures: Cardiac events (syncope, ventricular tachycardia/torsades de pointes, cardiac arrest, and sudden cardiac death) while patients received β-blocker therapy according to genotype. Results: Cardiac events among patients receiving β-blocker therapy occurred in 19 of 187 (10%) LQT1 patients, 27 of 120 (23%) LQT2 patients, and 9 of 28 (32%) LQT3 patients (P

Original languageEnglish
Pages (from-to)1341-1344
Number of pages4
JournalJournal of the American Medical Association
Issue number11
Publication statusPublished - Sep 15 2004

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Association of long QT syndrome loci and cardiac events among patients treated with β-blockers'. Together they form a unique fingerprint.

Cite this